Tumor markers in an evidence-based medicine

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 61, Issue 6, 2001, Pages 417-419

  Bormer O P ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC AGENT; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER REGISTRY; DIAGNOSTIC VALUE; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOASSAY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 17944377409     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365510152567040     Document Type: Editorial

References (10)

1. Serum turnout markers CA15-3, TPA, TPS, hCG and TATI in monitoring chemotherapy response in metastatic breast cancer
2. Interferences in immunoassays - Still a threat
3. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases
4. Preoperative serum prostate-specific antigen below 10 μg/L predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure
5. No randomised trial of prostate cancer screening in Norway
6. Ethics of a prostate cancer screening trial
7. Serum tumour markers in testicular and extragonadal germ cell malignancies
8. Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?
9. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society for Clinical Oncology
10. Doc, shouldn't we be getting some tests? Art of oncology: When the tumor is not the target